ABUS icon

Arbutus Biopharma

112 hedge funds and large institutions have $119M invested in Arbutus Biopharma in 2022 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 40 increasing their positions, 37 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

more call options, than puts

Call options by funds: $ | Put options by funds: $

more repeat investments, than reductions

Existing positions increased: | Existing positions reduced:

more ownership

Funds ownership:

more funds holding in top 10

Funds holding in top 10:

5% less funds holding

Funds holding: 118112 (-6)

9% less capital invested

Capital invested by funds: $131M → $119M (-$11.5M)

26% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 19

Holders
112
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
$4.81M
Puts
$2.63M
Net Calls
Net Calls Change

Top Buyers

1 +$5.81M
2 +$3.53M
3 +$1.94M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$1.26M
5
FCM
FourWorld Capital Management
New York
+$686K

Top Sellers

1 -$3.46M
2 -$2.2M
3 -$1.15M
4
BC
Brookfield Corp
Ontario, Canada
-$1.12M
5
Barclays
Barclays
United Kingdom
-$912K
Name Holding Trade Value Shares
Change
Change in
Stake
1
$20.4M
2
$14.1M
3
$12.7M
4
$11.3M
5
$9.49M
6
$5.75M
7
$5.31M
8
$5.19M
9
$4.88M
10
$4.84M
11
$3.7M
12
$2.43M
13
$1.98M
14
$1.5M
15
$1.37M
16
$1.15M
17
$962K
18
$887K
19
$781K
20
$774K
21
$654K
22
$596K
23
$595K
24
$543K
25
$542K